Genetics and 'Predictive Medicine':
Selling Pills, Ignoring Causes

GeneWatch UK Briefing Number 18
May 2002.

Genetic testing is being proposed as a way of identifying individuals who are 'genetically susceptible' to future disease. These 'high risk' individuals would then be encouraged to change unhealthy lifestyles, reduce their exposure to environmental hazards, or take medication before they become ill. This predictive/preventive approach sounds sensible but there are some important questions about the accuracy and negative effects of genetic testing:

What is predictive medicine?

The genetics revolution is already underway. In time we should be able to assess the risk an individual has of developing disease —not just for single gene disorders like cystic fibrosis but for our country's biggest killers—cancer and coronary heart disease—as well as those like diabetes which limit people's lives.

  The Rt Hon Alan Milburn, MP
Secretary of State for Health, January 2002 [1]

Several of the major pharmaceutical and biotechnology companies are promoting the idea of 'predictive medicine' or 'predisposition profiling.' This means using genetic tests to predict the chances that someone will contract serious illnesses like heart disease, cancer or mental illness, and then offering either lifestyle advice or medication with the aim of preventing the predicted illness. The benefits for the companies are that they can not only sell genetic tests but also expand the drug market (to those whom they have predicted as being at high risk of future illness).

Many claim that knowledge of genetic predisposition or susceptibility to major diseases heralds the prospect of shifting medical practice from its current emphasis on diagnosis and treatment to an exciting new era of prediction and prevention. For example, the European Commission has stated that: "A [genetic] revolution in health-care is anticipated through a move towards more prevention rather than cure. . ." [2]

However, there are concerns that for many people predictive medicine could do more harm than good—by worrying them and giving them medicines that they do not need—perhaps with unpleasant or even fatal side effects. This marketing strategy is sometimes known as 'pills for the healthy ill.' It could also take resources away from treating the sick and from preventing the underlying causes of many diseases (such as poor diets, lack of exercise, smoking and pollution).

How accurate will the predictions be?

If used with care, genetic tests can help diagnose inherited genetic diseases caused by problems with a single gene (such as cystic fibrosis) and help early treatment. Some forms of heart disease and cancer are inherited as single-gene diseases and some people in these high-risk families may also benefit from access to genetic tests. Around 5% of cancers are thought to be of this type, although having the faulty gene still does not necessarily mean someone will get the disease [3]. However, more tests for genetic susceptibility to the common forms of complex diseases such as cancer, heart disease and diabetes are being developed and an increased range of such tests is anticipated.

Common, complex diseases in the wider population are not usually inherited. They have many different causes including lifestyle and environment. A genetic test can only indicate a susceptibility to the disease with no certainty of the illness developing. Despite much research, genetic susceptibility to complex diseases such as heart disease, cancer and obesity has proved difficult to identify, with many poorly reproducible results. Except in a small percentage of cases, genes are poor predictors of future health [4]. Many people with the high risk form of the gene will not get the disease and many people without it will. For complex diseases, there is a real prospect of statistical studies identifying false associations between genes and the risk of future illness. A spurious link between a gene and a disease is often found in the first scientific study published, or the importance of the gene is exaggerated [5].

For both heart disease and cancer, many different genetic mutations in many different genes may each play a minor role, and a single genetic trait may predispose to one disease whilst being protective for another. Multiple environmental factors —particularly smoking, diet and exercise, and often infection and pollution—will also play a role and are usually more important than genetic make-up [6]. This makes it extremely difficult to quantify the risk using a genetic test. In addition, the more tests an individual undergoes, the more likely it is that some results will be false negatives or false positives [7]. In contrast, a single environmental exposure may contribute to many diseases and eliminating one exposure—such as smoking—can therefore reduce a large proportion of disease.

Which companies are involved?

Other [genetic] screens are in development... Next year, we want to introduce one focused on the skin, which would tell customers how sensitive their skin is to sunlight, chemicals and oxidative stress, how prone they are to skin cancer and what they can do about it. We're also looking at metabolisms important for people with depression, and how they can be affected by diet and medicines.

  Chris Martin
Chief Executive, Sciona Ltd [8]

Large pharmaceutical companies and small biotechnology companies are both researching and developing genetic tests (see Table 1). Alliances between the two types of company are common.

Table 1. The main companies involved in
developing and marketing genetic tests [9-12]

Planning to Sell
Genetic Test Kits
Identifying Genes Selling Genetic Tests
via the Internet
Roche
Abbott
Bayer
Johnson & Johnson
Beckman Dickinson
Qiagen
Digene
Cytocell
Visible Genetics
Celera Diagnostics
Gen-Probe
Orchid Biosciences
DiaDexus
Sequenom
Quest Diagnostics
Ads Shield
Promega
Myriad Genetics
Millenium
Genomics Collaborative
Exact Laboratories
Virologic
Applied Biosystems
Affymetrix
Decode
Genset
Third Wave Technologies
Oxagen
Sciona
DNA Dynamics Inc
D-FWMall.com
GeneLex Corp
HealthScreen America
GeneLink Inc
Bioheart Inc

GlaxoSmithKline has described the integration of diagnostics and pharmaceuticals—including genetic prediction as well as diagnosis of disease—as an area of significant added value for healthcare companies [13]. In 1997, it set up a joint venture with Incyte to develop and market genetic tests. Each still has a 20% stake in Diadexus, the company that has inherited SmithKline's exclusive rights to diagnostic patents for a protein which has been associated with an increased risk of heart disease.

Abbott Laboratories, Roche and Millennium are also pursuing new genetic tests in the hope of transforming the stagnant $20 billion diagnostics business into a growth industry. In 1997, Roche paid $11 billion to become the world leader in diagnostic test kits, with 17% of the market. In July 2001, Roche signed a five-year alliance with DeCode Genetics to develop and market genetic tests for major diseases. DeCode Genetics is using its Icelandic biobank (a genetic database) to focus on tests for genetic susceptibility to a range of diseases as a means of generating near-term revenue. DeCode Genetics already claims to have identified genes contributing to obesity, stroke and schizophrenia.

Genetic tests are expected to reach the market much more quickly than new medicines [14]. The US company, Myriad Genetics, is already generating revenue from genetic tests for the BRCA1 and BRCA2 genes that have been associated with genetic susceptibility to familial breast cancer. These tests have generated considerable controversy because of the patenting of these genes by Myriad and the high costs of the tests (around $2500). Many argue that the patents create a monopoly, seriously impede or prevent the further use of existing and more effective tests, and impede research and development.

Other companies are already selling genetic tests directly to the public but such sales are not regulated. The UK company Sciona describes itself as: "the first company in the world to offer genetic screening that will empower the individual to take actions to improve their health and well-being" by combining genetic testing with advice on diet [16]. The tests are now being sold on the high street via eleven Body Shop stores, as well as on the Internet. Sciona's tests have been criticised as meaningless and unethical by leading scientists [17] and GeneWatch UK has called on the Body Shop to withdraw them from sale.

Will genetic predictions lead to benefits to health?

The pharmaceutical company, GlaxoSmithKline has identified predisposition profiling—"the ability to assess an individual's risk for a disease or diseases so that medicine can be given to prevent illness"—as one key area of the new 'predictive medicine' and has argued that integrating genetic testing and pharmaceutical products will increase market size for pharmaceutical products and services [13].

However, it is questionable whether targeting medicines at people who are genetically susceptible but do not yet show any symptoms (the 'healthy ill') in this way would be safe and effective, except in high-risk families where the gene may be a good predictor of disease. In the wider population, one concern is that most of the people taking preventative medication on this basis would never have developed the disease. Most medications carry undesirable side effects, some of which are serious or even potentially fatal. In contrast, population-based prevention measures (such as banning tobacco advertising or encouraging more healthy diets) carry a low likelihood of adverse effects and are also less expensive.

Unlike most medicines, lifestyle changes such as stopping smoking, eating healthily and taking regular exercise have many benefits and protect against many different diseases. Some authors have suggested that a likely outcome of the genetic approach to disease prevention is that 'rich kids' will take large quantities of pills to try to avoid genetically predisposing risks without having to change their lifestyle [18]. This scenario would certainly be consistent with the strategies of the pharmaceutical companies who are seeking to increase the market for their products. However, by avoiding the need to change unhealthy lifestyles, this approach would lead to poorer health, even if there are no adverse side-effects from the medication.

The psychological impacts of genetic testing are also important and have been studied for single-gene inherited diseases, where counselling and the right to refuse a test (the right 'not to know') have been found to be important [19]. However, it is difficult to see how adequate, individual counselling can be given to the large proportion of the population likely to be identified as at high risk of common complex diseases, and how the highly uncertain risk predictions will be explained. Some people may be highly vulnerable to adverse psychological reactions to genetic predictions of stigmatised or feared conditions, such as mental illness and cancer.

There is also no current evidence to suggest that genetic information increases motivation or ability to change behaviour. Genetic information may even reduce motivation for some people, with some evidence that genetic tests can make a problem seem more worrying and less preventable than other types of test [20]. In other cases, motivation may increase, but the ability to address the problem may still be insufficient (for example, a genetic test may not help somebody to avoid pollution or overcome nicotine addiction). There is the potential to create a sense of fatalism in those who fail genetic tests and a sense of invulnerability in those who pass them.

Focusing help and advice on those identified as genetically susceptible is also likely to mean that the majority of cases of common diseases will not be diagnosed. Many people at risk of heart disease or cancer who are not identified as genetically susceptible may be misled into believing they can safely adopt unhealthy lifestyles. Where medical interventions are appropriate and widely beneficial (such as using nicotine replacement therapy to stop smoking or providing folic acid supplements to prevent spina bifida), there is no evidence to suggest that limiting access to those identified as genetically susceptible would increase health benefits overall.

Ignoring causes

There is a danger that the underlying socioeconomic or environmental causes of disease will be ignored in favour of a genetic approach to disease prevention. Some epidemiologists have argued that the genetic approach diverts limited resources, blames the victim and seldom assesses the relative importance of modifiable social and behavioural factors. This can result in using more and more advanced technology to study more and more trivial issues while the major population causes of disease are ignored [21].

Poverty is responsible for the most deaths worldwide and health inequalities are also of major significance within the UK and other European countries. Fatal heart disease in the UK is more than twice as common in Social Class V (the lowest class) as it is in Social Class I. Heart disease and cancer are strongly associated with the aggressive marketing of unhealthy diets, tobacco and alcohol and with reduced physical activity [22]. The variation in cancer incidence observed between different populations in the world is mainly a consequence of different lifestyle and environmental factors, which should be amenable to preventative interventions [23]. However, poorer groups are explicitly targeted by those marketing unhealthy products and are least likely to be reached by preventative measures [24]. Poor families are also more likely than those with higher incomes to live near polluting factories [25].

Nearly two thirds of men and over half of women in England are now overweight or obese, and obesity is continuing to rise faster than in most other European countries. At the current rate of increase, more than one in four adults will be obese by 2010 and at a higher risk of a range of major health problems including heart disease and adult-onset diabetes. The cause is obviously not an increase in 'genes for obesity', but unhealthy diets and lack of exercise—problems which need tackling across Government departments, using measures to integrate healthy eating and exercise into daily life, particularly in schools [26]. Too much emphasis on susceptibility genes for obesity could lead to the underlying causes of the epidemic being ignored, and the growing sale of diet or anti-cholesterol pills to the genetically susceptible instead.

Asthma is the most common chronic disease in children and has been increasing in developed countries in the past few decades. Although the causes are disputed, environmental or lifestyle factors—outdoors or in the home—must underlie the increase. One recent study found a link between children playing sport outdoors in areas of high air pollution and the development of asthma [27]. Such problems cannot be tackled by hunting for susceptibility genes for asthma but require Government policies to cut pollution [28].

Smokers are at an increased risk of more than 50 illnesses, of which 20 can be fatal. In countries where cigarette smoking has been common for several decades, such as the UK, about 90% of lung cancer, 15-20% of other cancers, 75% of chronic bronchitis and emphysema, and 25% of deaths from cardiovascular diseases at ages 35-69 years are attributable to tobacco [29]. Although genetic susceptibility may play a role in the development of some of these diseases, population-based measures to control tobacco marketing are likely to be both cheaper and more effective prevention measures than individual genetic testing for each smoking-related disease.

The potential for stigma and genetic discrimination

Ethical considerations, and legal, are fundamental to the whole issue of genetic testing. The consequences for individuals with regard to insurance and employment are also of the greatest importance, together with the implications for stigma and discrimination.

  Expert Working Group to the National Health Service Executive and the Human Genetics Commission [30]

In the future, people may be required to reveal genetic predictions about their health to their insurers or employers, or even to their school. There is the real prospect of discrimination based on a person's genetic make-up. A 'genetic underclass' could develop, which is excluded from insurance and employment [31].

A major concern is that genetic testing could be used to exclude those identified as genetically susceptible to hazardous substances from the workplace or from compensation rather than reducing or removing the hazard and improving the environment for all. This is a particular concern for diseases like cancer, which can be caused by many industrial chemicals and radiation, as employers may perceive genetic screening as a means of reducing liability [32].

Although genetic testing is not currently widespread, dozens of cases of exclusion from insurance or employment on the grounds of genetic test results have already been reported in the US [33,34]. There are no laws in the UK to prevent employers from refusing someone a job because of poor genetic test results, and there is only a temporary moratorium on the use of most genetic test results to set insurance premiums. The Government has also not signed the Council of Europe's Convention on Human Rights and Biomedicine, which prohibits discrimination against people because of their genetic make-up.

The broader implications of widespread genetic testing

The linkage of genetic and health information and the potential for using the [Biobank UK] database for a wide variety of analyses aimed at determining susceptibility to disease raises important issues about confidentiality, security of data and informed consent. These concerns were raised as recently as Monday by Gene Watch, and they were the subject of a debate in the House of Lords yesterday. The Government takes these concerns seriously and will not allow the work to proceed until they have been satisfactorily addressed.

  The Rt Hon Alan Milburn
Secretary of State for Health [1]

Any company, government or institution undertaking genetic tests can create a database that links people's samples, genetic make-up and lifestyle information (known as 'biobanks'). Biobanks raise many additional ethical issues, which the Government is currently considering in relation to the proposed national research project, Biobank UK [35-37].

As well as the potential for genetic discrimination, issues include:

If biobanks are owned by commercial companies, genetic and lifestyle information may also be used to direct-market vitamin supplements, skin creams and medication, potentially to vulnerable individuals identified by the company as being at high risk following genetic testing.

Conclusions

Without proper controls, genetic testing could be used to massively expand the drug market to healthy people identified as at high genetic risk. Many people could receive unnecessary medication and suffer the associated side effects. The underlying causes of heart disease and cancer, and current increases in obesity, asthma and adult-onset diabetes could be ignored, with serious implications for future health.

Genetic testing should only be used in carefully controlled circumstances where it is of proven benefit to health. Tests should not be sold over-the-counter in high street stores. It is essential that people are:

Genetic tests need urgent regulation by a statutory body to ensure their validity and usefulness, and laws must be put in place to ban genetic discrimination and control access to genetic information.

Genetic determinism (the over-emphasis of genetic factors in disease) must not detract from tackling the underlying causes of many major diseases, including health inequalities, poor diets, lack of exercise, smoking and pollution.

More detailed information on these issues is available in a recent report written by GeneWatch UK for the World Health Organisation [38].

References

  1. Speech by Rt Hon Alan Milburn MP, Secretary of State for Health at the international conference 'Genetics and Health -- a Decade of Opportunity',16 January 2002. Available on www.doh.gov.uklspeechesljan2002milburngenetics.htm
  2. Commission of the European Communities (2001), Towards a Strategic Vision of Life Sciences and Biotechnology: Consultation Document, 4 September 2001.
  3. Vineis, P, Schulte, P, McMichael, AJ (2001), Misconceptions about the use of genetic tests in populations. The Lancet, 357, 709-712.
  4. Holtzman, NA, Marteau, TM (2000), Will Genetics Revolutionize Medicine? New England Journal of Medicine, 343,141-144.
  5. Ioannidis, JPA, Ntzani, EE, Trikalinos, TA, Contopoulos-Ioannidis, DG (2001), Replication Validity of Genetic Association Studies. Nature Genetics, 29, 306-309.
  6. Baird, P (2001), The Human Genome Project, Genetics and Health. Community Genetics, 4, 77-80.
  7. Levitt, M (1999), The Ethics and Impact on Behaviour of Knowledge about One's Own Genome. British Medical Journal, 319, 1283.
  8. Madell, S (2002), Genetic Testing... on the High Street. Health and Fitness magazine, April 2002.
  9. "Roche Leads Molecular Diagnostics Charge". Nature Biotechnology, 20, 6-7, January 2002.
  10. "Gene Mappers: Diagnostic Tests are the Future". Matthew Herper, Forbes.com, 25 October 2001.
  11. "Patient, Diagnose thyself'. Signals Magazine, 2 January 2001. Available on www.signalsmag.com.
  12. Divining Disease. Forbes.com, 13 November, 2000. Available on www.forbes.com.
  13. Gilham I, Rowland, T(2001), Predictive Medicine: Potential benefits from the integration of diagnostics and pharmaceuticals. International Journal of Medical Marketing, 2,18-22.
  14. Sander, C (2000), Genomic Medicine and the Future of Health Care. Science, 287, 1977-1978."France Challenges Patent for Genetic screening of Breast Cancer". British Medical Journal, 323, 589, 15 September 2001.
  15. Sciona (2001), "Sciona Spearheads Individual Healthcare Revolution: Gene Technology Delivered to the Public". Sciona Press Release, 17 May 2001. Available on www.sciona.com.
  16. Meek, J (2002), Public 'Misled by Gene Test Hype'. The Guardian, 12 March, 2002. Available on www.guardian.co.uk.
  17. Bloom, BR, Trach, DD (2001), Genetics and Developing Countries. British Medical Journal, 322, 1006-1007.
  18. Evers-Kiebooms, Welkenhuysen, M, Claes, E, Decruyenaere, M, Denayer, L (2000), The Psychological Complexity of Predictive Testing for Late Onset Neurogenetic Diseases and Hereditary Cancers: Implications for Multidisciplinary Counselling and for Genetic Education. Social Science and Medicine, 51, 831-841.
  19. Marteau, TM, Lerman, C (2001), Genetic Risk and Behavioural Change. British Medical Journal, 322, 1056-1059.
  20. Pearce, N (1996), Traditional Epidemiology, Modern Epidemiology, and Public Health. American Journal of Public Health, 86(5), 678-683.
  21. United Nations (2001), Health and Sustainable Development. UN Economic and Social Council Report E/CN. 1712001/PC/6,2 March 2001.
  22. Parkin, DM (2001), Global Cancer Statistics in the Year 2000. The Lancet Oncology, 2, 533-543.
  23. Yach, D (2001), Chronic Disease and Disability of the Poor: Tackling the Challenge. Development, 44(1), 59-65.
  24. Friends of the Earth (1999), The Geographic Relation Between Household Income and Polluting Factories. Friends of the Earth Trust, April 1999. Available on www.foe.co.uk/resource/reports-income_pollution.
  25. National Audit Office (2001), Tackling Obesity in England, 15 February 2001. Available on www.naogov. uk/pn/0O-01/0001 220.htm.
  26. McConnell, R, Berhane, K, Gilliland, F, London, SJ, Islam, T, Gauderman, WJ, Avol, E, Margolis, HG, Peters, JM (2002), Asthma in Children Exposed to Ozone: A Cohort Study. The Lancet, 359, 386-391.
  27. "Blair's Top Scientist Calls for Petrol Car Ban". The Independent, 17 February, 2002. Available on www.independent.co.uk.
  28. ASH Fact Sheets and Tobacco: Global Trends. www.ash.org.uk.
  29. "Laboratory Services for Genetics". Report of an expert working group to the NHS Executive and the Human Genetics Commission, August 2000. Available on www.doh.gov.uklgeneticsl laboratory.htm.
  30. GeneWatch UK (2001), Genetic Testing in Insurance and Employment: A New Form of Discrimination. Briefing 15, June 2001.
  31. Schulte, PA, Lomax, GP, Ward, EM, Colligan, MJ (1999), Ethical Issues in the Use of Genetic Markers in Occupational Epidemiologic Research. Journal of Occupational and Environmental Medicine, 41(8), 639-46.
  32. US Department of Labor, Department of Health and Human Services, Equal Opportunity Commission, Department of Justice (1998), Genetic Information and the Workplace. 20 January 1998. Available on www.nhgri. nih.gov/HGPlReports/genetics-workplace.html.
  33. Kaufert, PA (2000), Health Policy and the New Genetics. Social Science and Medicine, 51, 821-829.
  34. Meek, J (2002), Safeguards Fail at Gene Bank Says Watchdog. The Guardian, 14 January, 2002.
  35. GeneWatch UK (2001), Human Bio-Collections: Who Benefits from Gene Banking. Briefing 14, April 2001.
  36. GeneWatch UK (2001), Giving Your Genes to Biobank UK: Questions to Ask.
  37. World Health Organization (2002), Human Genetic Technologies: Implications for Preventative Health Care, A report for WHO by GeneWatch UK, WHO/ HGNIRep/02.1 . Available by email request from boulyjenkow©who.int.

GeneWatch UK, a nonprofit British organization whose goal is to ensure that genetic technologies are developed and used in the public interest. Since this was written, the Body Shop stopped selling Sciona's tests and Sciona changed its policy so they now destroy the test samples (although they keep the data).

This article was revised on January 23, 2003.

Links to Recommended Vendors